Literature DB >> 26464510

Structural insights into species-specific features of the ribosome from the pathogen Staphylococcus aureus.

Zohar Eyal1, Donna Matzov1, Miri Krupkin1, Itai Wekselman1, Susanne Paukner2, Ella Zimmerman1, Haim Rozenberg1, Anat Bashan1, Ada Yonath3.   

Abstract

The emergence of bacterial multidrug resistance to antibiotics threatens to cause regression to the preantibiotic era. Here we present the crystal structure of the large ribosomal subunit from Staphylococcus aureus, a versatile Gram-positive aggressive pathogen, and its complexes with the known antibiotics linezolid and telithromycin, as well as with a new, highly potent pleuromutilin derivative, BC-3205. These crystal structures shed light on specific structural motifs of the S. aureus ribosome and the binding modes of the aforementioned antibiotics. Moreover, by analyzing the ribosome structure and comparing it with those of nonpathogenic bacterial models, we identified some unique internal and peripheral structural motifs that may be potential candidates for improving known antibiotics and for use in the design of selective antibiotic drugs against S. aureus.

Entities:  

Keywords:  antibiotic resistance; potential advanced pleuoromutilin; protein biosynthesis; species specificity

Mesh:

Substances:

Year:  2015        PMID: 26464510      PMCID: PMC4629319          DOI: 10.1073/pnas.1517952112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  79 in total

1.  High resolution structure of the large ribosomal subunit from a mesophilic eubacterium.

Authors:  J Harms; F Schluenzen; R Zarivach; A Bashan; S Gat; I Agmon; H Bartels; F Franceschi; A Yonath
Journal:  Cell       Date:  2001-11-30       Impact factor: 41.582

Review 2.  Resistance to linezolid caused by modifications at its binding site on the ribosome.

Authors:  Katherine S Long; Birte Vester
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

3.  Structural basis of the ribosomal machinery for peptide bond formation, translocation, and nascent chain progression.

Authors:  Anat Bashan; Ilana Agmon; Raz Zarivach; Frank Schluenzen; Joerg Harms; Rita Berisio; Heike Bartels; Francois Franceschi; Tamar Auerbach; Harly A S Hansen; Elizaveta Kossoy; Maggie Kessler; Ada Yonath
Journal:  Mol Cell       Date:  2003-01       Impact factor: 17.970

4.  Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae.

Authors:  Annie Canu; Brigitte Malbruny; Maëlle Coquemont; Todd A Davies; Peter C Appelbaum; Roland Leclercq
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

5.  Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010.

Authors:  Susanne Paukner; Helio S Sader; Zrinka Ivezic-Schoenfeld; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2013-07-08       Impact factor: 5.191

6.  Erythromycin resistance mutations in ribosomal proteins L22 and L4 perturb the higher order structure of 23 S ribosomal RNA.

Authors:  S T Gregory; A E Dahlberg
Journal:  J Mol Biol       Date:  1999-06-18       Impact factor: 5.469

7.  Topical retapamulin ointment (1%, wt/wt) twice daily for 5 days versus oral cephalexin twice daily for 10 days in the treatment of secondarily infected dermatitis: results of a randomized controlled trial.

Authors:  Lawrence Charles Parish; Joseph Lucius Jorizzo; John Jeffrey Breton; Joseph William Hirman; Nicole Elizabeth Scangarella; Ribhi Mohammad Shawar; Scott Matthew White
Journal:  J Am Acad Dermatol       Date:  2006-10-06       Impact factor: 11.527

8.  Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections.

Authors:  W T Prince; Z Ivezic-Schoenfeld; C Lell; K J Tack; R Novak; F Obermayr; G H Talbot
Journal:  Antimicrob Agents Chemother       Date:  2013-02-19       Impact factor: 5.191

9.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

10.  New pleuromutilin derivatives with enhanced antimicrobial activity.II.Structure-activity correlations.

Authors:  H Egger; H Reinshagen
Journal:  J Antibiot (Tokyo)       Date:  1976-09       Impact factor: 2.649

View more
  40 in total

1.  Combined Effect of the Cfr Methyltransferase and Ribosomal Protein L3 Mutations on Resistance to Ribosome-Targeting Antibiotics.

Authors:  Kevin K Pakula; Lykke H Hansen; Birte Vester
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

2.  In Vitro Activity of Lefamulin Tested against Streptococcus pneumoniae with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United States.

Authors:  Rodrigo E Mendes; David J Farrell; Robert K Flamm; George H Talbot; Zrinka Ivezic-Schoenfeld; Susanne Paukner; Helio S Sader
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

3.  Low Prevalence of Gram-Positive Isolates Showing Elevated Lefamulin MIC Results during the SENTRY Surveillance Program for 2015-2016 and Characterization of Resistance Mechanisms.

Authors:  Rodrigo E Mendes; Susanne Paukner; Timothy B Doyle; Steven P Gelone; Robert K Flamm; Helio S Sader
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

4.  Revising the Structural Diversity of Ribosomal Proteins Across the Three Domains of Life.

Authors:  Sergey Melnikov; Kasidet Manakongtreecheep; Dieter Söll
Journal:  Mol Biol Evol       Date:  2018-07-01       Impact factor: 16.240

5.  Avilamycin and evernimicin induce structural changes in rProteins uL16 and CTC that enhance the inhibition of A-site tRNA binding.

Authors:  Miri Krupkin; Itai Wekselman; Donna Matzov; Zohar Eyal; Yael Diskin Posner; Haim Rozenberg; Ella Zimmerman; Anat Bashan; Ada Yonath
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-19       Impact factor: 11.205

6.  Characterization of the Core Ribosomal Binding Region for the Oxazolidone Family of Antibiotics Using Cryo-EM.

Authors:  Alexander Wright; Kieran Deane-Alder; Edward Marschall; Rebecca Bamert; Hari Venugopal; Trevor Lithgow; David W Lupton; Matthew J Belousoff
Journal:  ACS Pharmacol Transl Sci       Date:  2020-05-13

7.  Kinetics of drug-ribosome interactions defines the cidality of macrolide antibiotics.

Authors:  Maxim S Svetlov; Nora Vázquez-Laslop; Alexander S Mankin
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-11       Impact factor: 11.205

8.  In vitro antibacterial activity of α-methoxyimino acylide derivatives against macrolide-resistant pathogens and mutation analysis in 23S rRNA.

Authors:  Hiroyuki Sugiyama; Ippei Yoshida; Mayumi Ueki; Katsuhiko Tanabe; Akira Manaka; Keiichi Hiramatsu
Journal:  J Antibiot (Tokyo)       Date:  2017-01-11       Impact factor: 2.649

Review 9.  How Macrolide Antibiotics Work.

Authors:  Nora Vázquez-Laslop; Alexander S Mankin
Journal:  Trends Biochem Sci       Date:  2018-07-24       Impact factor: 13.807

10.  Structures of the orthosomycin antibiotics avilamycin and evernimicin in complex with the bacterial 70S ribosome.

Authors:  Stefan Arenz; Manuel F Juette; Michael Graf; Fabian Nguyen; Paul Huter; Yury S Polikanov; Scott C Blanchard; Daniel N Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-21       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.